Kornimate/medical-research-clean huggingface dataset:
effectiveness of medical taping concept in cancer patients

Conditions: Cancer-related Problem/Condition

Summary: nausea and vomiting are two of the side effects associated with the most common antineoplastic chemotherapy treatments. the medical taping concept (mtc) is an economical technique, easy to apply. this is a technique that may help reduce nausea and vomiting after application of chemotherapy in cancer patient.

nausea and vomiting are two of the side effects associated with the most common antineoplastic chemotherapy treatments. there are some studies that support the use of physical measures such as tens or acupuncture to lessen these effects. the medical taping concept (mtc) is an economical technique, easy to apply and few side effects. in some manuals on this technique the possibility that it may act to reduce nausea and vomiting described. sim but after a comprehensive literature search have not found jobs to support these assumptions. with this work, the research team will attempt to obtain evidence on the effects of its application in the areas of influence of the dermatome t7 and t8. for this, two adhesive tapes of this type of bandage is placed on the front and back on a group of patients after receiving chemotherapy session and compared with a control group that will apply this technique outside the dermatome indicated . both groups will receive antiemetics according to the service routine. if the hypothesis were positive it could extend the application of this simple technique to cancer patients from other centers in order to help reduce nausea and vomiting.

Eligibility criteria:
inclusion criteria: * neoadjuvant and adjuvant breast cancer * to have been diagnosed with a severe comorbid disorder * to have received at least the first cycle of emetogenic chemotherapy exclusion criteria: * not suffer nausea or vomiting episodes in the previous cycle of chemotherapy, * to shower inability to report nausea and / or vomiting.
study on the rehabilitation treatment of knee osteoarthritis based on icf

Conditions: Knee Osteoarthritis

Summary: to solve the existing knee osteoarthritis;koa) clinical norms and guidelines have low operability, disconnection between treatment plan and specific evaluation results, difficulty in achieving individualized intervention and other problems, on the one hand, we need to develop chinese expert consensus or clinical path based on evidence-based medicine to adapt to china's national conditions, on the other hand, is more important in the koa clinical process introduces a set of tools to translate evidence-based medicine evidence into specific, actionable treatments, thus, a more flexible, more comprehensive and three-dimensional, adaptable, targeted, more conducive to the promotion of the individual integration koa rehabilitation intervention program.


Eligibility criteria:
inclusion criteria: * neither knee had undergone knee replacement, and no knee replacement had been performed in recent half a year planning to have a knee replacement; volunteered to participate in the study and signed the informed consent. exclusion criteria: * people with consciousness disorder, cognitive disorder, severe mental illness, unable to accurately express their own will, or unable to cooperate with the completion of various assessments and treatment
measurement of serum levels of two antiepileptic drugs during conversion in patients with epilepsy

Conditions: Epilepsy

Summary: this study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (aed) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.


Eligibility criteria:
inclusion criteria: * 16 years old or older. * have confident diagnosis of epilepsy. * have been on the medication valproate for at least 3 months and is currently on a stable daily dose. * male or female; females of child-bearing potential must have negative pregnancy test at screen and must agree to use an acceptable birth control method. exclusion criteria: * a history of hypersensitivity to the drug being studied. * currently being treated with or has been treated in the past with the drug being studied. * undergoing polytherapy treatment with the medication valproate and one or more other antiepileptic drug(s). * if undergoing treatment with vagal nerve stimulation, has had device implanted more than 30 days prior to enrollment. * has taken an investigational drug or the medication felbatol within the previous 30 days. * is abusing alcohol and/or other substances.

Keywords: epilepsy monotherapy conversion
biochemical and genetic markers in liver diseases

Conditions: Biochemical and Genetic Markers in Liver Diseases

Summary: investigation of biochemical and genetic markers in liver disease that might have an influence on the course of the disease


Eligibility criteria:
inclusion criteria: * suffering from liver disease * age of 18 years or older * agreement to participate in study exclusion criteria: * younger than 18 years * no consent to participate
sphenopalatine nerve block for headache tx360

Conditions: Headache; Migraine

Summary: the primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.


Eligibility criteria:
inclusion criteria: * are 18 - 65 years of age * present to emergency department (ed) triage with chief complaint of crescendo-onset anterior/frontal headache (affecting frontal, temporal, orbital, maxillary, and mandible region) * have a normal neurological exams exclusion criteria: * are less than 18 years old or greater than 65 * have any focal neurological dysfunction signs or symptoms * have a posterior/occipital/cervicogenic source predominance of headache * are febrile (oral temperature 37.7 c or 100 f) or signs of acute or chronic sinusitis, such as congestion, has been present more than 10 days, there is a high fever, the nasal mucus is an abnormal color, or complains of face pain or headaches * have self treated with pain medication or anti-emetic 4 hours prior to arrival * have a history of peripheral vascular disease, cancer, or hiv infection * are known to be pregnant

Keywords: headache migraine
addictive threshold of nicotine

Conditions: Smoking Addiction

Summary: to determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.

the purpose of this project is to determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, and reinforcement in smokers with different levels of dependence. participants will have an adaptation session followed by 4 test days. the adaptation session will familiarize the participants with study procedures. in each test day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. this will be followed by 4 choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline to be administered by the research staff. reinforcement will be assessed with the percentage of nicotine choices during the choice trials. the discrimination is the percentage of correctly identified nicotine and saline infusions. rewarding effects will be assessed with the "pleasurable effects" composite score of the drug effects questionnaire (deq).

Eligibility criteria:
inclusion criteria: * to contact their primary care provider when necessary. * adults, aged 21 to 59 years. individuals less than 21 will be excluded because the minimum age for purchasing tobacco products is 21 in our state. the upper age is set at 59 because there are no previous iv nicotine studies that enrolled smokers over the age of 59. * smoking at least for one year and more frequently than once a week, smoking status confirmed with a semi-quantitative urine nicotine test. smokers will be stratified based on the level of dependence, assessed with the ftnd scores (heatherton et al. 1991) (low or no dependence 4 and moderate or high level of dependence 5. * in good health as verified by medical history, screening examination, and screening laboratory tests. * for women, report using acceptable birth control methods. exclusion criteria: * history of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study * regular current use of certain psychotropic medications (such as mood stabilizers, antipsychotics, or anxiolytics being prescribed to treat bipolar disorder, psychosis or anxiety spectrum disorders, respectively) * current untreated alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine * for women, pregnant as determined by pregnancy screening, or breastfeeding * seeking (or undergoing) treatment for tobacco dependence or smoking.
care in multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: this study is structured around three main aims. in aim 1, investigators will conduct community-based participatory research (cbpr) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (ms). aim 2 will investigate the impact of childhood adversity on ms outcomes among individuals with relapsing-remitting ms (rrms), among whom 70% belong to a group historically under-represented in ms research: black, hispanic, or poverty-impacted. aim 2 procedures involve two visits that include a research blood draw and an mri scan. in aim 3, investigators will conduct interviews and surveys to explore environmental and social factors affecting quality of life for minority ms patients.


Eligibility criteria:
inclusion criteria: aim 1 - * aged ≥18 years * diagnosis of rrms (fulfill international criteria for relapsing remitting (rrms)) * 70% self-identifying as a black, hispanic, or poverty-impacted (up to 138% of the federal poverty level) individual,and * fluent in english or spanish. aim 2 - * aged ≥18-29 years * diagnosis of rrms (fulfill international criteria for relapsing remitting (rrms)) * 70% self-identifying as a black, hispanic, or poverty impacted, and * fluent reading in english or spanish * pediatric onset ms (ms onset before age 18 and age at time of enrollment is 18-25) or adult-onset ms (ms onset at age 18 or older and age at time of enrollment is 19-29) * disease duration below 8 years aim 3 - aim 3 will enroll the first 20 participants from aim 2 who meet the following criteria: * completed at least 80% of study data in the cross-sectional study/aim 2. * a total of 70% must self-identify as black, hispanic, or meet criteria for poverty impacted. * interviews will be evenly split between participants with high (top quartile) and low (bottom quartile) of promis-10 scores. exclusion criteria: * primary or secondary progressive ms * inability to consent. * ms relapse within 30 days prior to study entry * other major neurologic or psychiatric illness
efficacy and safety of praga formulation in the treatment of neuropathic pain

Conditions: Neuropathic Pain

Summary: the purpose of this study is to evaluate the efficacy and safety of praga formulation in the treatment of neuropathic pain.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * participants of 18 years and older; * diagnosis of type 2 or type 1 diabetes for at least 1 year; * no change in antidiabetic medication winthin 3 months; * diagnosis of painful sensorimotor diabetic polyneuropathy; * presence of at least one of the following symptoms: i. numbness in the toes, feet and / or legs; ii. paresthesias (tingling and / or neuropathic pain) in the toes, feet and / or legs. * presence of at least one of the following signs: i. symmetrical hypoesthesia of tactile, thermal or painful sensation (s) in the distal region of the legs; ii. hypoactive or abolished achilles reflexes; * glycated hemoglobin ≤ 11%; * score ≥ 12 points on the lanss pain scale (leeds assessment of neuropathic symptoms and signs); j) participants with moderate to severe pain, a score ≥ 4 on the numerical pain scale (0-10 points); * participants with moderate to severe neuropathic pain who recorded in the diary a minimum of 4 of the 7 days from the period to assess the baseline pain score. exclusion criteria: * known hypersensitivity to the formula components used during the clinical trial; * history of alcohol and/or substance abuse within 2 years; * pregnant women, breastfeeding or planning to become pregnant, or women with the potential to become pregnant who are not using a reliable method of contraception; * history of pernicious anemia, uncontrolled hypothyroidism, chronic hepatitis b; * hiv diagnosis; * history of neurological disorder unrelated to diabetic neuropathy; * non-responders to previous pregabalin treatment; * high variability in the baseline pain score; * other conditions that may alter the sensitivity in the affected dermatome or in the area involved in neuropathic pain that may confuse pain assessment; * severe psychiatric condition; * cognitive decline that affect the participant from correctly answering the scales and questionnaires; * clinically relevant cardiac abnormalities, which at the researcher's discretion represent a risk to participation in the trial; * participant who has amputated lower limb due to complications from diabetes; * renal failure, defined by the estimated glomerular filtration rate \[egfr\] \<60 ml / min / 1.73 m2.
a local retrospective observational study to evaluate the treatment patterns of mcrpc patients in belgium treated with radium-223

Conditions: Prostatic Neoplasms, Castration-Resistant

Summary: the aim of this non interventional study is to describe the proportion of belgian mcrpc patients which were treated with 1 to 4 and 5 to 6 radium-223 injections and the patient characteristics which are potentially associated with this proportion.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases * all consecutive patients who started radium-223 treatment between 22 december 2014 and 01 june 2017 * availability of medical records during the observation period (22dec2013 - 01jun2018) exclusion criteria: * patients treated with radium-223 for any reason before 22 december 2014 (for example an interventional trial) * patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period * patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the radium-223 treatment period

Keywords: radium-223 metastatic castration-resistant prostate cancer crpc phase iv
predicting disease progression in atrial fibrillation: a multiparametric approach for prognostic marker identification and personalized patient management

Conditions: Atrial Fibrillation (AF)

Summary: this project leverages artificial intelligence (ai) to decipher atrial fibrillation (af) progression and optimize treatment strategies. by recruiting a diverse cohort of 322 af patients, we will gather a robust multiparametric dataset including clinical, genetic, electrocardiographic, and echocardiographic data. harnessing ai, we will extract and correlate hidden components within ecg-obtained p-wave data and echocardiographic studies with atrial fibrosis, culminating in an atrial fibrosis score (afs). the afs will non-invasively predict fibrosis extent and af clinical progression, including metrics like rehospitalization, cardiac morbidity, and mortality. ultimately, this endeavor aims to improve af patient management, significantly reducing healthcare costs, and enhancing patient quality of life.


Eligibility criteria:
inclusion criteria: * history of paroxysmal or persistent atrial fibrillation * clinical indication for atrial fibrosis (af) ablation according to the 2020 esc guidelines exclusion criteria: * age below 18 years old * refusal to sign consent * noncompliance with the study protocol
clinical efficacy in relief of dyspnea by hvni: evaluation of new device equivalence

Conditions: Dyspnea; Hypercapnia; Respiratory Insufficiency

Summary: this study will evaluate the ability of a new high velocity nasal insufflation \[hvni\] device design to effect ventilation and related physiological responses relative to the current hvni device design.

the objective of this study is to evaluate the ability of a new hvni device to improve ventilation, dyspnea, and related physiological responses relative to the conventional precision flow device design, with which there are published clinical outcomes data. it is hypothesized that the new hvni device design (v2.0) will be comparable at relieving patient dyspnea when compared to the conventional hvni device design (precision flow).

Eligibility criteria:
inclusion criteria: * adult inpatients (18 years of age and older) * demonstrated severe dyspnea at baseline (borg rated perceived dyspnea \[rpd\] (scale 0-10) of 3 or higher) * severe baseline hypercarbia/hypercapnia of 55 mmhg or higher as measured by tcpco2 or arterial or venous blood gas exclusion criteria: * patient has unstable cardiovascular condition * significant unilateral or bilateral nasal occlusion * inability to provide informed consent * pregnancy * known contraindication to perform steps of the protocol * absence of spontaneous respiration or known contraindication to hvni * inability to use hvni therapy * agitation or uncooperativeness * determined by the clinician to be sufficiently unstable or unsuitable for this study
retrospective study using next generation sequencing (ngs) on biological samples to improve genetic counseling for patients with previously explored craniofacial midline defects.

Conditions: Holoprosencephaly

Summary: holoprosencephaly, or hpe, is the most common congenital cerebral malformation in humans and the most severe of a group of pathologies related to a deficiency of the shh signalling pathway (sonic hedgehog shh-d). it is characterized by severe cerebral and craniofacial abnormalities. the regulation of shh concentration is therefore crucial for correct craniofacial development. despite the recent identification of about 20 genes, 70% of cases of ehpe and craniofacial midline abnormalities of genetic origin do not have a molecular diagnosis. it is therefore important to continue the search for new candidate genes to improve the understanding of brain and facial development and to improve genetic counseling for these families. the development of next-generation sequencing (ngs) technologies opens up the possibility of studying the exome or even the genome in a single manipulation. the latter type of analysis is particularly well suited to the discovery of new genes and will therefore improve the care of patients and their families.


Eligibility criteria:
inclusion criteria: * patients with craniofacial midline facial anomalies (cmfla) collected for genetic analysis * patients and relatives for whom consent for research-related genetic testing is available. a "trio" - patient and both parents is required for analysis of variant segregation and determination of mode of transmission. * for patients who are minors, parental authority(ies) who have given consent for research genetic testing. * affiliation to a social security scheme * patient and parents do not object to their participation in the research. * in the case of a patient who has reached the age of majority since the initial consent was obtained, a patient who has given consent to proceed with genetic analyses for research purposes. exclusion criteria: * adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
infection prophylaxis in total joint replacement

Conditions: Periprosthetic Joint Infection

Summary: osteoarthritis (oa) is the most common cause of disability in older adults worldwide affecting 7% of the global population, or more than 500 million people globally. total joint replacements (tjr) can help bring relief to those with osteoarthritis when other treatment options are no longer helpful. infection is the main reason hip and knee replacements "fail". failure leads to repeat surgeries that are often more complicated and less likely to be successful than the first surgery. reducing the risk of infection is extremely important, antiseptic washes and antibiotics may help us do that. after joint replacement surgery, orthopaedic surgeons wash and clean the surgical wound to lower the risk of infection. the goal of this clinical trial is to determine if the use of antiseptic solutions to wash the surgical site and placing an antibiotic directly into the wound will reduce the number of infections requiring reoperation. patients having total joint replacements will be randomized (like flipping a coin) to receive 6 possible combinations of washes and / or antibiotics. participants will be followed for one year after tjr to compare the rate of infection in each group.


Eligibility criteria:
inclusion criteria: 1. patients 18 years of age or older. 2. undergoing primary or aseptic revision tjr. 3. no contraindications to study interventions. 4. informed consent (participant or substitute decision maker) obtained and willing to comply with the protocol. exclusion criteria: 1. received antibiotics for any reason in the two weeks prior to their tjr. 2. chronic or acute infection at or near the tjr site. 3. prior history of periprosthetic joint infection including any reoperation due to infection. 4. undergoing surgery for a diagnosis of a fracture. 5. open infected wounds on affected limb. 6. undergoing bilateral tjr. 7. currently enrolled in a study that does not permit co-enrollment. 8. prior enrollment in the trial including the pilot study 9. any condition or circumstance, which in the opinion of the investigator, interferes with assessments or completion of the trial.

Keywords: arthroplasty